Adaptive Biotechnologies (Adaptive Biotechnologies) Operating Income : $-193.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Operating Income?

Adaptive Biotechnologies's Operating Income for the three months ended in Mar. 2024 was $-48.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-193.2 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Adaptive Biotechnologies's Operating Income for the three months ended in Mar. 2024 was $-48.8 Mil. Adaptive Biotechnologies's Revenue for the three months ended in Mar. 2024 was $41.9 Mil. Therefore, Adaptive Biotechnologies's Operating Margin % for the quarter that ended in Mar. 2024 was -116.45%.

Warning Sign:

Adaptive Biotechnologies Corp operating margin has been in a 5-year decline. The average rate of decline per year is -5.1%.

Adaptive Biotechnologies's 5-Year average Growth Rate for Operating Margin % was -5.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Adaptive Biotechnologies's annualized ROC % for the quarter that ended in Mar. 2024 was -61.74%. Adaptive Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -150.61%.

Adaptive Biotechnologies Operating Income Historical Data

The historical data trend for Adaptive Biotechnologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Operating Income Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-78.39

-152.82

-208.97

-200.19

-201.61

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial															-57.19	-47.82	-50.96	-45.64	-48.76

Adaptive Biotechnologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-193.2 Mil.

Adaptive Biotechnologies (NAS:ADPT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Adaptive Biotechnologies's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-195.048 * ( 1 - 0% )	/	( (322.645	+	309.157)	/ 2 )
=	-195.048	/	315.901
=	-61.74 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	661.134	-	16.316	-	( 346.401	-	max(0, 88.015	-	410.188	+	346.401	))
=	322.645

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	620.323	-	20.084	-	( 308.872	-	max(0, 82.952	-	374.034	+	308.872	))
=	309.157

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Adaptive Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-178.16	/	( ( (120.323 + max(-14.844, 0))	+	(116.259 + max(-8.196, 0)) )	/	2 )
=	-178.16	/	( ( 120.323	+	116.259 )	/	2 )
=	-178.16	/	118.291
=	-150.61 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(37.969	+	14.448	+	11.37)	-	(16.316	+	48.63	+	13.685)
=	-14.844

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(42.021	+	13.291	+	9.85)	-	(20.084	+	46.87	+	6.404)
=	-8.196

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Adaptive Biotechnologies's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-48.762	/	41.873
	=	-116.45 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Adaptive Biotechnologies Operating Income Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Executives

Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg	director	C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy	director	5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102